Bollinger Band Squeeze Stocks
CCCC appears in our Bollinger Band Squeeze Stocks screen. This means the stock is showing a tight volatility setup, where the Bollinger Bands have narrowed and price may be preparing for a larger breakout move.
C4 THERAPEUTICS INC (CCCC) Stock Price & Overview
NASDAQ:CCCC • US12529R1077
Current stock price
3.07 USD
-0.05 (-1.6%)
At close:
3.07 USD
0 (0%)
After Hours:
The current stock price of CCCC is 3.07 USD. Today CCCC is down by -1.6%. In the past month the price increased by 22.8%. In the past year, price increased by 99.35%.
CCCC Key Statistics
52-Week Range1.21 - 3.82
Current CCCC stock price positioned within its 52-week range.
1-Month Range2.3 - 3.2
Current CCCC stock price positioned within its 1-month range.
- Market Cap
- 299.571M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.36
- Dividend Yield
- N/A
CCCC Stock Performance
Today
-1.6%
1 Week
+6.23%
1 Month
+22.80%
3 Months
+42.79%
Longer-term
6 Months +25.31%
1 Year +99.35%
2 Years -51.27%
3 Years +1.66%
5 Years -90.73%
10 Years N/A
CCCC Stock Chart
CCCC Stock Screens
CCCC currently appears in the following ChartMill screener lists.
CCCC Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CCCC. When comparing the yearly performance of all stocks, CCCC is one of the better performing stocks in the market, outperforming 93.13% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
CCCC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CCCC. No worries on liquidiy or solvency for CCCC as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CCCC Earnings
On February 26, 2026 CCCC reported an EPS of -0.18 and a revenue of 11.02M. The company beat EPS expectations (41.9% surprise) and beat revenue expectations (67.19% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$0.18
Revenue Reported11.016M
EPS Surprise 41.90%
Revenue Surprise 67.19%
CCCC Forecast & Estimates
14 analysts have analysed CCCC and the average price target is 11.8 USD. This implies a price increase of 284.46% is expected in the next year compared to the current price of 3.07.
For the next year, analysts expect an EPS growth of 16.32% and a revenue growth -32.15% for CCCC
Analysts
Analysts85.71
Price Target11.8 (284.36%)
EPS Next Y16.32%
Revenue Next Year-32.15%
CCCC Groups
Sector & Classification
CCCC Financial Highlights
Over the last trailing twelve months CCCC reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS increased by 9.93% compared to the year before.
Income Statements
Revenue(TTM)35.95M
Net Income(TTM)-104.99M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.24% | ||
| ROE | -40.92% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%63.27%
Sales Q2Q%112.79%
EPS 1Y (TTM)9.93%
Revenue 1Y (TTM)1.02%
CCCC Ownership
Ownership
Inst Owners76.8%
Shares97.58M
Float86.91M
Ins Owners3.78%
Short Float %18.59%
Short Ratio5.99
CCCC Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CCCC
Company Profile
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Company Info
IPO: 2020-10-02
C4 THERAPEUTICS INC
490 Arsenal Way, Suite 120
Watertown MASSACHUSETTS 02472 US
CEO: Andrew J. Hirsch
Employees: 104
Phone: 16172310700
C4 THERAPEUTICS INC / CCCC FAQ
What does CCCC do?
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
What is the stock price of C4 THERAPEUTICS INC today?
The current stock price of CCCC is 3.07 USD. The price decreased by -1.6% in the last trading session.
Does CCCC stock pay dividends?
CCCC does not pay a dividend.
What is the ChartMill rating of C4 THERAPEUTICS INC stock?
CCCC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is C4 THERAPEUTICS INC (CCCC) stock traded?
CCCC stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of CCCC stock?
C4 THERAPEUTICS INC (CCCC) operates in the Health Care sector and the Biotechnology industry.